BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kimura S, Harashima H. Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB. Pharmaceutics 2020;12:E1216. [PMID: 33334049 DOI: 10.3390/pharmaceutics12121216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kasina V, Mownn RJ, Bahal R, Sartor GC. Nanoparticle delivery systems for substance use disorder. Neuropsychopharmacol . [DOI: 10.1038/s41386-022-01311-7] [Reference Citation Analysis]
2 Saeb S, Assche JV, Loustau T, Rohr O, Wallet C, Schwartz C. Suicide gene therapy in cancer and HIV-1 infection: An alternative to conventional treatments. Biochem Pharmacol 2021;197:114893. [PMID: 34968484 DOI: 10.1016/j.bcp.2021.114893] [Reference Citation Analysis]
3 Kimura S, Harashima H. Non-invasive gene delivery across the blood-brain barrier: present and future perspectives. Neural Regen Res 2022;17:785-7. [PMID: 34472471 DOI: 10.4103/1673-5374.320981] [Reference Citation Analysis]
4 El Ganainy SO, Cijsouw T, Ali MA, Schoch S, Hanafy AS. Stereotaxic-assisted gene therapy in Alzheimer's and Parkinson's diseases: therapeutic potentials and clinical frontiers. Expert Rev Neurother 2022;:1-17. [PMID: 35319338 DOI: 10.1080/14737175.2022.2056446] [Reference Citation Analysis]
5 Menon S, Armstrong S, Hamzeh A, Visanji NP, Sardi SP, Tandon A. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. Front Neurol 2022;13:852003. [DOI: 10.3389/fneur.2022.852003] [Reference Citation Analysis]
6 Mitra S, Gumusgoz E, Minassian BA. Lafora disease: Current biology and therapeutic approaches. Rev Neurol (Paris) 2021:S0035-3787(21)00611-1. [PMID: 34301405 DOI: 10.1016/j.neurol.2021.06.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Singh RK, Soliman A, Guaitoli G, Störmer E, von Zweydorf F, Dal Maso T, Oun A, Van Rillaer L, Schmidt SH, Chatterjee D, David JA, Pardon E, Schwartz TU, Knapp S, Kennedy EJ, Steyaert J, Herberg FW, Kortholt A, Gloeckner CJ, Versées W. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2. Proc Natl Acad Sci U S A 2022;119:e2112712119. [PMID: 35217606 DOI: 10.1073/pnas.2112712119] [Reference Citation Analysis]
8 Fishman PS, Fischell JM. Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases. Front Neurol 2021;12:749047. [PMID: 34803886 DOI: 10.3389/fneur.2021.749047] [Reference Citation Analysis]
9 Jensen TL, Gøtzsche CR, Woldbye DPD. Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord. Front Mol Neurosci 2021;14:695937. [PMID: 34690692 DOI: 10.3389/fnmol.2021.695937] [Reference Citation Analysis]
10 Mendonça MCP, Kont A, Aburto MR, Cryan JF, O'Driscoll CM. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System. Mol Pharm 2021;18:1491-506. [PMID: 33734715 DOI: 10.1021/acs.molpharmaceut.0c01238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Yamada Y, Ishizuka S, Arai M, Maruyama M, Harashima H. Recent advances in delivering RNA-based therapeutics to mitochondria. Expert Opin Biol Ther 2022;:1-11. [PMID: 35543589 DOI: 10.1080/14712598.2022.2070427] [Reference Citation Analysis]